- Home
- ZVRA vs RCKT Comparison
ZVRA vs RCKT Comparison
Compare ZVRA & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZVRA | RCKT |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.7M | 428.6M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZVRA | RCKT |
|---|---|---|
| Price | $8.36 | $3.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $21.71 | ★ $30.27 |
| AVG Volume (30 Days) | 879.9K | ★ 2.1M |
| Earning Date | 03-10-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $84,388,000.00 | N/A |
| Revenue This Year | $333.64 | N/A |
| Revenue Next Year | $44.19 | N/A |
| P/E Ratio | $15.78 | ★ N/A |
| Revenue Growth | ★ 244.60 | N/A |
| 52 Week Low | $6.19 | $2.19 |
| 52 Week High | $13.16 | $11.11 |
Technical Indicators
Market Signals| Indicator | ZVRA | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 41.54 |
| Support Level | $8.25 | $3.07 |
| Resistance Level | $8.73 | $3.32 |
| Average True Range (ATR) | 0.44 | 0.19 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 9.12 | 33.11 |
Price Performance
Historical ComparisonAbout ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.